Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Insmed, Inc.

INSM

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Last trade $121.45
Day change -$1.43 (-1.16%)
Day range $118.61 – $123.65
Volume 1,303,108
Market cap $26.96B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$26.96B
Price / earnings
—
Price / book
37.12×
Price / sales
17.74×
EV / sales
17.86×
EV / EBITDA
-50.28×

Profitability

Earnings per share
-$2.76
Return on assets
-27.21%
Return on equity
-83.39%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.79×
Current ratio
2.86×
Quick ratio
2.59×
Cash ratio
0.66×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$627.58M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for INSM, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$524.43M$425.49M$305.96M$263.84M$142.34M$107.42M$92.82M$104.44M
Cost of revenue$78.22M$67.21M$47.42M$44.22M$29.37M$28.08M$21.28M$26.15M
Gross profit$446.21M$358.27M$258.54M$219.62M$112.98M$79.34M$71.55M$78.29M
Selling, general and administrative$253.03M$247.47M$247.26M$212.48M$186.38M$154.76M$147.55M$142.52M
Research and development$269.96M$210.03M$209.49M$254.91M$186.42M$177.19M$152.58M$179.73M
Total operating expenses$535.58M$359.82M$411.86M$539.37M$478.98M$392.22M$319.69M$308.71M
Operating income-$89.37M-$1.55M-$153.32M-$319.75M-$366.01M-$312.88M-$248.14M-$230.41M
Interest expense-$20.41M-$20.27M-$20.08M-$20.6M-$20.38M-$21.25M-$21.57M-$21.55M
Income before taxes-$97.65M-$11.37M-$162.1M-$326.93M-$368.7M-$320.44M-$255.67M-$234.28M
Income taxes$2.67M$1.87M$1.47M$1.55M$1.32M$1.24M$912K$1.27M
Net income-$100.32M-$13.24M-$163.56M-$328.49M-$370.02M-$321.69M-$256.58M-$235.55M
Net income attributable to common shareholders-$100.32M-$13.24M-$163.56M-$328.49M-$370.02M-$321.69M-$256.58M-$235.55M
EBITDA-$80.97M$3.71M-$148.31M-$314.19M-$362.01M-$309.13M-$244.99M-$227.67M
Basic earnings per share-$0.46-$0.06-$0.76-$1.53-$1.75-$1.70-$1.42-$1.31
Diluted earnings per share-$0.46-$0.06-$0.76-$1.53-$1.75-$1.70-$1.42-$1.31

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and Madrigal

Zacks highlights four commercial-stage biotechnology companies demonstrating strong revenue growth and market penetration: TG Therapeutics (Briumvi for MS), BioCryst Pharmaceuticals (Orladeyo for HAE), Insmed (Brinsupri and Arikayce for respiratory diseases), and Madrigal Pharmaceuticals (Rezdiffra for MASH). All four companies show consistent quarterly sales increases, expanding patient adoption, and strategic initiatives to broaden their commercial reach through new formulations, international expansion, and label expansions.

Zacks Investment Research

INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance

Insmed (INSM) reported third-quarter 2026 revenues of $524.4 million, surging 268% year-over-year and beating estimates. Brinsupri sales jumped 29% sequentially to $400.1 million, while Arikayce generated $124.4 million. The company raised 2026 guidance for both products and stock jumped 15% on the announcement. However, the company posted a wider-than-expected loss of 46 cents per share, and operating expenses rose significantly.

Zacks Investment Research

Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know

Kura Oncology is expected to report a quarterly loss of $0.83 per share with revenues of $22.2 million for Q3 2026. While the company has a positive Earnings ESP of +3.61%, its Zacks Rank of #4 (Sell) makes it difficult to predict an earnings beat. The combination of these factors suggests KURA is not a compelling earnings-beat candidate.

Zacks Investment Research

Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Insmed is expected to report a quarterly loss of $0.33 per share with revenues of $501.26 million when it releases Q3 2026 results on October 29. While revenues are projected to surge 252.2% year-over-year, the company's Earnings ESP of -3.48% combined with a Zacks Rank #3 makes it difficult to predict an earnings beat. The stock has beaten consensus estimates in 2 of the last 4 quarters.

Zacks Investment Research

INSM Stock Slides on CFO Exit, Reiterates '26 Sales View

Insmed's stock fell nearly 7% following the announcement that CFO Sara Bonstein will step down effective October 30 after nearly seven years in the role. Despite the leadership transition, the company reaffirmed its 2026 revenue guidance, expecting Brinsupri revenues of $1.25-$1.40 billion and Arikayce sales of $450-$470 million. The decline reflects investor uncertainty about the unexpected departure of a key executive during a critical growth phase.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Mar 3, 20111-for-10reverse split